Thus, blocking CCL2 with soluble CCR2 fragment or inhibition of CCR2 with blocking antibody could decrease tumor accumulation of MDSCs in the tumor bone metastases model by injecting prostate cancer cells directly into murine tibiae, making it a potential target for anti-tumor therapy (101). Here, CCR2 is linked to prostate carcinoma.